A recent series by Spotlight PA detailed pipeline safety in the commonwealth through the eyes of the statewide Mariner East pipeline system, which cuts through this region (“Along Mariner East pipelines, secrecy and a patchwork of emergency plans leave many at risk and in the dark”). So often with this... Read more.

At least one cruise line that operates out of U.S. ports is seeking volunteers for trial voyages.... Read more.

Philips Stellarex low-dose drug-coated balloon November 07, 2020 Meta-analysis of two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of a patient-level meta-analysis that confirms the safety profile of its Stellarex drug-coated balloon (DCB) at four years. Including data from two major randomized controlled trials (RCTs), the results show no difference in mortality between patients treated with the Stellarex DCB and those treated with percutaneous angioplasty (PTA), the current standard of care. The meta-analysis, which represents the highest level of the evidence pyramid, was presented at the virtual 2020 Vascular Interventional Advances conference (VIVA20). The meta-analysis found that over four years, there was no significant difference in survival among patients treated with the Stellarex DCB (85.7%) compared to those treated with PTA (85.6%). The data includes two Stellarex RCTs: the ILLUMENATE EU RCT and the ILLUMENATE Pivotal RCT, comprised of 589 patients in the U.S. and Europe followed up to four years with a high compliance on vital status data. “The meta-analysis reinforces previously presented results from the ILLUMENATE RCTs, demonstrating low mortality rates each year through four years, with no difference in rates between the two patient cohorts,” said Sean Lyden, MD, Chairman of the Department of Vascular Surgery, Cleveland Clinic (U.S.), who presented the data. Dr. Lyden is also co-Primary Investigator for the ILLUMENATE Pivotal trial, one of the two RCTs included in the meta-analysis, and a paid consultant to Philips. “This independent, patient-level meta-analysis continues to provide consistent, long-term data for a large group of patients.” In addition to demonstrating no significant difference in all-cause mortality between patients treated with the Stellarex DCB and those treated with PTA (14.3% vs. 14.4%), the results of the meta-analysis also show no difference in cardiovascular mortality (3.6% vs. 4.0%) and non-cardiovascular mortality (10.8% vs. 10.9%). “The results of this study confirm the safety and performance of our unique Stellarex low-dose drug-coated balloon,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “We are committed to providing healthcare providers with accurate and transparent data in order to help them make an informed decision on the optimal treatment for each patient with peripheral arterial disease. Stellarex, with its low drug dose and unique drug coating composition, is a logical choice for those who require this option.” Featuring Philips EnduraCoat technology, a unique coating consisting of a polyethylene glycol excipient with amorphous and crystalline paclitaxel particles dispersed in it, Stellarex .035” DCB is unlike any other drug-coated balloon for the treatment of peripheral artery disease. EnduraCoat technology provides efficient drug transfer and effective drug residency coupled with high coating durability and minimal particulate loss, thereby enabling a low therapeutic drug dose. Philips’ Image Guided Therapy business provides complete procedural solutions of systems, smart devices, disease-specific software and services for minimally invasive procedures, helping caregivers decide, guide, treat and confirm the right therapy for each patient during their procedure. For further information, please contact: Mark GrovesPhilips Global Press OfficeTel.: +31 631 639 916E-mail: [email protected] Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622 698 001E-mail : [email protected] About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachment Philips Stellarex low-dose drug-coated balloon... Read more.

Ample Hunting Opportunities Prompt Safety - Tip Reminders | Illinois News... Read more.

Adams had no designation on the Seahawks� practice report Friday, meaning he�s set to...... Read more.

Saint John Transit has collaborated with students and teachers in multiple schools to promote the importance o...... Read more.

Retailers and stores are ramping up precautions ahead of the holiday season.... Read more.

HIS interest in antivenom and snakebite treatment has become a big part of his life.... Read more.

Poster presentations at the American College of Rheumatology (ACR) annual meeting shed light on performance of adalimumab products by various measures.... Read more.

STEPANAKERT, NOVEMBER 7, ARMENPRESS. Safety measures are being taken in Artsakh’s capital Stepanakert.... Read more.

Food safety officials in Visakhapatnam served notices to as many as 22 restaurants for violating safety norms and the Covid-19 protocol.... Read more.

ORONO � Every Maine county experienced some level of drought in 2020, with September reported as the driest on record, according to the National Weather Service. Because the autumn rains Maine received may not benefit thirsty gardens and wells until later in the ...... Read more.

Abatacept for JIA Passes Long - term Safety Trial... Read more.

The two organizations signed a three-year memorandum of understanding on November 2.... Read more.

Crashes temporarily closed the Glenn Highway at Turpin Street and at Eklutna.... Read more.

The Royal Canadian Mounted Police are stepping in to help enforce federal safety rules aboard BC Ferries vessels.... Read more.

“When is the turkey going to be ready?” someone asked.... Read more.

While the protests have been largely peaceful, officials have been worried by the gatherings and concerned about the relentless accusations.... Read more.

IAEA Deputy Director General Mikhail Chudakov thanked Belarus' leadership for close and active cooperation with the IAEA in ensuring the safety of the Belarusian nuclear power plant as he addressed the staff and builders of the Belarusian nuclear power plant.... Read more.

Ample hunting opportunities prompt safety-tip reminders - The Wilton Bulletin... Read more.

Singapore to reopen nightlife pubs for 2 months with Covid safety measures on Business Standard. Singapore will allow a limited number of nightlife establishments to reopen for two months with Covid-19 safety measures from December, nine months after it was shut after the coronavirus pandemic hit... Read more.